Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution.
复制标题
作者：
急性红白血病（AML-M6）是急性髓细胞白血病（AML）的一种罕见亚型;它被认为具有不良预后。从1980年1月1日至2008年5月21日，108例新诊断的AML-M6患者在德克萨斯大学医学博士。安德森癌症中心（UT-MDACC）。一半（50%）有骨髓增生异常综合征（MDS）病史，而对照组（其他AML亚型患者）为41%（p=0.05）。在AML-M6患者中，低风险细胞遗传学更常见（69%对46%，p<0.001）。AML-M6患者的完全缓解率为63%，对照组为58%（p = 0.285）。AML-M6患者的中位无病生存期（DFS）为31周，对照组为49周（p = 0.004）。AML-M6患者的中位总生存期（OS）为33周，而对照组为42周（p = 0.13）。在DFS和OS的多因素分析中，AML-M6不是独立的危险因素。急性红白血病通常与先前诊断的MDS和低风险核型相关。AML-M6的诊断本身并不意味着预后更差，对这种疾病的治疗决定应该由众所周知的AML预后因素指导。
Acute erythroleukemia (AML-M6) is an uncommon subtype of acute myeloid leukemia (AML); it is considered to have a poor prognosis. From January 1st, 1980 to May 21st, 2008, 108 patients with newly diagnosed AML-M6 were seen at the University of Texas – M.D. Anderson Cancer Center (UT-MDACC). Half (50%) had a history of myelodysplatic syndrome (MDS), compared to 41% in our control group (patients with other AML subtypes) (p=0.05). Poor risk cytogenetics was more common in patients with AML-M6 (69% versus 46%, p<0.001). Complete remission rates were 63% for patients with AML-M6, comparing to 58% for the control group (p = 0.285). Median disease free survival (DFS) for patients with AML-M6 was 31 weeks, versus 49 weeks for the control group (p = 0.004). Median overall survival (OS) of patients with AML-M6 was 33 weeks, compared to 42 weeks for the control group (p = 0.13). On multivariate analysis for DFS and OS, AML-M6 was not an independent risk factor. Acute erythroleukemia is commonly associated with a previous diagnosis of MDS and poor risk karyotype. The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well know AML prognostic factors.